AbbVie has agreed to pay $1.4 billion to buy Aliada Therapeutics. The acquisition will give AbbVie control of an Alzheimer’s ...

Glioblastoma is the most common and deadliest form of brain cancer. Patients face a bleak prognosis – the average survival ...

The purchase is the latest in a slew of efforts to invest in its neuroscience portfolio as Humira faces generic competition.

With a new way to break the blood-brain barrier, an Aliada Therapeutics deal could give the North Chicago drugmaker's ...

Repurposing Drug Shows Promise in Fighting Aggressive ... scientists used ultrasound technology to penetrate the blood-brain barrier and provide a small dose of a chemotherapy and ...

Boston-based Aliada gets drugs across the blood-brain barrier (BBB) by leveraging receptors that transport substances into the brain. Lead Aliada program ALIA-1758 is an antibody engineered with ...

The purchase of Aliada Therapeutics is “interesting for a number of reasons,” according to a Stifel analyst, one of which is ...

A research team at Lund University in Sweden has discovered a certain type of cell—foam cells—in patients with the aggressive ...

Unlock the potential of focused ultrasound in brain medicine. Learn about its groundbreaking use in delivering chemotherapy ...

AbbVie (ABBV) announced Monday that it is buying Aliada Therapeutics for $1.4 billion. The deal includes Aliada’s lead drug ...